New combo therapy aims to boost platelets in ITP patients

NCT ID NCT07669675

Not yet recruiting Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding baricitinib to standard TPO-RA therapy helps adults with immune thrombocytopenia (ITP) who did not respond to TPO-RA alone. One hundred participants will be randomly assigned to receive either baricitinib plus TPO-RA or TPO-RA alone for 14 days. The main goal is to see if the combination leads to a better platelet count response without needing rescue treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Baricitinib (a JAK inhibitor) plus a TPO-RA (hetrombopag or eltrombopag)
What this could lead to: If it works, this could offer a new combination treatment option for people with immune thrombocytopenia who do not respond to standard TPO-RA therapy alone.
What could go wrong: This is a small, early-phase trial (phase 2) with only 100 participants, so results may not apply to everyone. Baricitinib can increase infection risk and other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ITP - IMMUNE THROMBOCYTOPENIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.